Honeybee (Apis mellifera L.) venom (BV) is a good candidate for development as a therapeutic modality for the treatment of acne vulgaris. However, BV has been restricted in the development of medical agents because BV has not been registered as an Active Pharmaceutical Ingredient (API). The aim of this study was to evaluate viral safety of BV, as biological origin agents. The viral diseases of honeybees were reported at least 18 virus types. Using RT-PCR we evaluated infected honeybees, BV isolated bee venom sac from virus infected honeybee, and BV collected from honeybees using BV collector for the presence of the seven bee viruses, complete genome sequence including Sacbrood virus (SBV), Black queen cell virus (BQCV), Deformed wing virus (DWV), Chronic bee paralysis virus (CBPV), Acute bee paralysis virus (ABPV), Kashmir bee virus (KBV), and Israeli acute paralysis virus (IAPV). The SBV, BQCV, DWV, CBPV, ABPV, KBV, and IAPV were not detected both BV isolated bee venom sac from virus infected honeybee and BV collected from honeybees using BV collector. According to these results, we have meanwhile observed that BV and BV sac might be safety for bee viruses contamination. We suggest that BV could be used a good candidate for API.
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